• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Upcoming dvm360 Conferences
Resources
CBD in Pets
CE Requirements by State
Contests
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
Veterinary Heroes
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

IDEXX launches quantitative reference laboratory test for Lyme disease

July 1, 2003

A new canine test for Lyme disease allows veterinarians to not only identify infection, but also decide on a therapeutic plan and monitor their treatment choice.

A new canine test for Lyme disease allows veterinarians to not only identify infection, but also decide on a therapeutic plan and monitor their treatment choice.Lyme C6 Quantitative Antibody Test is a reference laboratory test that, when used as a follow-up test to the in-house rapid assay screening test, provides veterinarians with the latest diagnostic information for effectively managing Lyme disease.With the discovery of the C6 antigen and the dogs unique antibody response to it, IDEXX developed the Snap 3Dx as a screening tool. And the company just announced the availability of this new test, which provides veterinarians with a two-tiered approach to Lyme disease testing.Veterinarians can screen all dogs for Lyme accurately and economically with the in-house Snap 3Dx and then follow up positive results with the Lyme C6 Quantitative Antibody Test to accurately measure a dogs antibody level to C6, reports Dr. Terri Wheeler of IDEXX Laboratory Services. The antibody level will help determine the relative spirochetal burden, weigh treatment options and measure the effectiveness of a treatment approach.In addition to the tests high sensitivity and specificity, initial studies show that C6 antibody levels also correlate with a dogs spirochetal load, Wheeler explains.In one study, dogs exposed to B. burgdorferi had a dramatic increase in tissue spirochetes when measured with a quantitative PCR. These same dogs, when treated with antibiotics, have a dramatic decrease in tissue spirochetes (Straubinger RK. J Clin Microbiol. 200; 38 (6): 2191-2199). C6 antibody levels correlate to these spirochetal loads, rising dramatically after B. burgdorferi exposure, and then dropping off rapidly after treatment with antibiotics. (Phillip MT, et al. J Infectious Dis. 2001; 184(7): 870-878.)IDEXX adds that as a result of these many attributes, the C6 antibody performs more like an antigen test than an antibody test.Recent research indicates that subclinical infections are more common than previously thought and may actually outnumber clinical infections. Cornell University research also demonstrated that 70 percent of 16 dogs infected with Lyme disease had a three-to-six-day episode of varying degrees of lameness, with the first episode occurring at a median of 71 days post-infection, Wheeler explains.With introduction of the test, IDEXX is recommending screening dogs and further characterizing positive dogs by quantifying antibody levels.

For fastest response call (800) 340-6215.

Related Content:

Products
 Vetstoria releases its Fill Rate platform
Vetstoria releases its Fill Rate platform
Communicating the importance of genetic screening
Communicating the importance of genetic screening
Study reveals Zymox Otic Plus is beneficial and effective
Study reveals Zymox Otic Plus is beneficial and effective

Advertisement

Latest News

Partners for Health Pets and VHMA collaboration publish white paper

Vetstoria releases its Fill Rate platform

What's new with the "Dentistry Lane" across the veterinary profession?

Meet the BlackDVM Network

View More Latest News
Advertisement